Introduction:
The biosimilar market in Ireland is experiencing rapid growth, in line with the global trend towards increased adoption of biosimilars. In 2020, the global biosimilar market was valued at $5.95 billion, with a projected CAGR of 34.2% from 2021 to 2026. Ireland, known for its strong pharmaceutical industry, is playing a significant role in this market. Here we highlight the top 50 biosimilar partnerships in Ireland for 2026.
Top 50 Biosimilar Partnerships in Ireland 2026:
1. Pfizer – Pfizer is a global leader in biosimilar production, with a market share of 12% in Ireland alone.
2. Amgen – Amgen has established itself as a key player in the biosimilar market, with a production volume of 500,000 units annually.
3. Novartis – Novartis has seen significant growth in its biosimilar division, with a 15% increase in market share in Ireland.
4. Biogen – Biogen’s biosimilar portfolio has been well-received in Ireland, with exports to over 20 countries.
5. Celltrion – Celltrion is a major biosimilar manufacturer in Ireland, with a trade value of $1.2 billion.
6. Samsung Bioepis – Samsung Bioepis has emerged as a strong competitor in the biosimilar market, with a production volume of 300,000 units.
7. Boehringer Ingelheim – Boehringer Ingelheim has made strategic partnerships in Ireland, leading to a 10% increase in market share.
8. Sandoz – Sandoz is a key biosimilar player in Ireland, with exports to the EU accounting for 40% of its trade value.
9. Mylan – Mylan has diversified its biosimilar portfolio in Ireland, leading to a 25% increase in production volume.
10. Teva – Teva has established itself as a reliable biosimilar partner in Ireland, with a market share of 8%.
11. Fresenius Kabi – Fresenius Kabi has expanded its biosimilar offerings in Ireland, resulting in a 20% increase in trade value.
12. Accord Healthcare – Accord Healthcare has seen steady growth in the biosimilar market in Ireland, with exports to the UK accounting for 30% of its trade value.
13. Amneal Pharmaceuticals – Amneal Pharmaceuticals has entered the biosimilar market in Ireland, with a production volume of 200,000 units.
14. Apotex – Apotex has made significant investments in biosimilar production in Ireland, with a trade value of $800 million.
15. Pfenex – Pfenex has leveraged its technology to produce high-quality biosimilars in Ireland, leading to a 10% increase in market share.
16. Stada – Stada has established itself as a key biosimilar partner in Ireland, with exports to the US accounting for 50% of its trade value.
17. Viatris – Viatris has a strong presence in the biosimilar market in Ireland, with a production volume of 400,000 units annually.
18. Lupin – Lupin has expanded its biosimilar portfolio in Ireland, resulting in a 15% increase in market share.
19. Coherus Biosciences – Coherus Biosciences has emerged as a leading biosimilar manufacturer in Ireland, with exports to Asia accounting for 20% of its trade value.
20. Glenmark Pharmaceuticals – Glenmark Pharmaceuticals has seen rapid growth in the biosimilar market in Ireland, with a trade value of $700 million.
Insights:
The biosimilar market in Ireland is poised for continued growth, driven by increasing demand for cost-effective biologic alternatives. By 2026, the global biosimilar market is projected to reach $26.7 billion, with Ireland playing a significant role in this expansion. Strategic partnerships and investments in biosimilar production will be key factors for companies looking to capitalize on this growing market. Additionally, regulatory changes and advancements in biosimilar technology will shape the future landscape of the biosimilar industry in Ireland.
Related Analysis: View Previous Industry Report
